Starpharma Holdings Limited (ASX: SPL) announced the results from its first radiotherapeutic candidate, DEP® lutetium which is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP® dendrimer scaffold.
The study was conducted at the University of Queensland’s Centre for Advanced Imaging, and the effectiveness of two dose treatments of DEP® lutetium were evaluated in a human prostate cancer model. DEP® lutetium demonstrated statistically significant & durable anticancer activity and was very well tolerated in both dose regimens.
At AEST 12:14 PM, SPL shares are trading at A$1.115, up 5.189% from the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.